The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

44 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Synthesis and quantitative structure-activity relationships of diclofenac analogues.EBI
Ciba-Geigy
Three-dimensional pharmacophores from binding data.EBI
Ciba-Geigy
New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.EBI
Ciba-Geigy
N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors.EBI
Ciba-Geigy
Dual angiotensin converting enzyme/thromboxane synthase inhibitors.EBI
Ciba-Geigy
Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor.EBI
Ciba-Geigy
4-Amidinoindan-1-one 2'-amidinohydrazone: a new potent and selective inhibitor of S-Adenosylmethionine decarboxylase.EBI
Ciba-Geigy
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 2. Synthesis and biological activity of 8-(benzenesulfonamido)-7-(3-pyridinyl)octaonic acid and related compounds.EBI
Ciba-Geigy
Definition and display of steric, hydrophobic, and hydrogen-bonding properties of ligand binding sites in proteins using Lee and Richards accessible surface: validation of a high-resolution graphical tool for drug design.EBI
Ciba-Geigy
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.EBI
Ciba-Geigy
Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase.EBI
Ciba-Geigy
Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease.EBI
Ciba-Geigy
2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.EBI
Ciba-Geigy
Benzofuro[2,3-c]pyridin-6-ols: synthesis, affinity for opioid-receptor subtypes, and antinociceptive activity.EBI
Ciba-Geigy
Synthesis, opioid receptor binding profile, and antinociceptive activity of 1-azaspiro[4.5]decan-10-yl amides.EBI
Ciba-Geigy
Enkephalinase inhibitors. 1. 2,4-Dibenzylglutaric acid derivatives.EBI
Ciba-Geigy
New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.EBI
Ciba-Geigy
Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors.EBI
Ciba-Geigy
Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds.EBI
Ciba-Geigy
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 5. Synthesis and evaluation of enantiomers of 8-[[(4-chlorophenyl)sulfonyl]amino]-4-(3-pyridinylalkyl)octanoic acid.EBI
Ciba-Geigy
S-adenosylmethionine decarboxylase inhibitors: new aryl and heteroaryl analogues of methylglyoxal bis(guanylhydrazone).EBI
Ciba-Geigy
Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors.EBI
Ciba-Geigy
Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.EBI
Ciba-Geigy
Structure-based design of inhibitors of purine nucleoside phosphorylase. 4. A study of phosphate mimics.EBI
Ciba-Geigy
Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase.EBI
Ciba-Geigy
Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.EBI
Ciba-Geigy
Dicarboxylic acid dipeptide neutral endopeptidase inhibitors.EBI
Ciba-Geigy
Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists.EBI
Ciba-Geigy
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.EBI
Ciba-Geigy
Inhibition of peptidylglycine alpha-amidating monooxygenase by N-substituted homocysteine analogs.EBI
Ciba-Geigy
Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists.EBI
Ciba-Geigy
Synthesis and biological activity of some transition-state inhibitors of human renin.EBI
Ciba-Geigy
2H-[1]benzopyrano[3,4-b]pyridines: synthesis and activity at central monoamine receptors.EBI
Ciba-Geigy
Synthesis and aromatase inhibitory activity of novel 1-(4-aminophenyl)-3-azabicyclo[3.1.0]hexane- and -[3.1.1]heptane-2,4- diones.EBI
Ciba-Geigy
Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives.EBI
Ciba-Geigy
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic acids.EBI
Ciba-Geigy
2-substituted 3-(aminooxy)propanamines as inhibitors of ornithine decarboxylase: synthesis and biological activity.EBI
Ciba-Geigy
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-(3-(3-pyridinyl) propyl)octanoic acid and analogs.EBI
Ciba-Geigy
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 3. Pyridinylalkyl-substituted 8-[(arylsulfonyl)amino]octanoic acids.EBI
Ciba-Geigy
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereofBDB
Samumed
Synthesis and structure-activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-beta inhibitors.BDB
Bristol-Myers Squibb
Design, synthesis, and biological evaluation of potent c-Met inhibitors.BDB
Amgen
Biaryl amide compounds as kinase inhibitorsBDB
Novartis